Myo-004 / MitoRx Therap - LARVOL DELTA

Characterisation of Myo4 in the murine diet-induced obesity model: a first-in-class anti-obesogenic muscle-preserving small molecule metabolic modulator. (EASD 2025) - "Clinical trials such as STEP1, STEP4, and SUSTAIN8 with semaglutide showed lean mass accounted for 40% of weight loss, with similar results observed with liraglutide (SCALE), tirzepatide (SURMOUNT-1), and dulaglutide (AWARD-11)... Myo4 is a novel anti-obesogenic and muscle-preserving therapeutic, usable as monotherapy for obesity requiring weight loss with muscle preservation, or in combination with GLP-1RA to prevent loss of SkM mass/function."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

New data backs Myo4 for obesity treatment (Drug Target Review) - "MitoRx Therapeutics Limited (MitoRx), a platform biotech company pioneering mitochondrial-targeted persulfide modifiers, has announced new preclinical data demonstrating the efficacy of its small molecule drug candidate, Myo4, in treating obesity. The results were presented in a poster session at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago....The study highlights Myo4’s ability to restore insulin sensitivity in a widely used murine diet-induced obesity (DIO) model, building on earlier findings that it reduces fat while preserving muscle and bone health."

Preclinical • Obesity